Open access · CC-BY
via OpenAlex
NAD+-boosting agent nicotinamide mononucleotide potently improves mitochondria stress response in Alzheimer’s disease via ATF4-dependent mitochondrial UPR
Xi Xiong, Jialong Hou, Yi Zheng, Tao Jiang, Xuemiao Zhao, Jinlai Cai, Jiani Huang, Haijun He, Jiaxue Xu, Shuangjie Qian, Yao Lü, Xinshi Wang, Wenwen Wang, Qianqian Ye, Shuoting Zhou
Cell Death and Disease · 2024 · ▲ 56 citations
Abstract
Abstract Extensive studies indicate that mitochondria dysfunction is pivotal for Alzheimer’s disease (AD) pathogenesis; while cumulative evidence suggests that increased mitochondrial stress response (MSR) may mitigate neurodegeneration in AD, explorations to develop a MSR-targeted therapeutic strategy against AD are scarce. We combined cell biology, molecular biology, and pharmacological approaches to unravel a novel molecular pathway by which NAD + -boosting agent nicotinamide mononucleotide (NMN) regulates MSR in AD models. Here, we report dyshomeostasis plasma UPR mt -mitophagy-mediated MSR profiles in AD patient samples. NMN restores NAD + metabolic profiles and improves MSR through the ATF4-dependent UPR mt pathway in AD-related cross-species models. At the organismal level, NAD + repletion with NMN supplementation ameliorates mitochondrial proteotoxicity, decreases hippocampal synaptic disruption, decreases neuronal loss, and brain atrophy in mice model of AD. Remarkably, omics features of the hippocampus with NMN show that NMN leads to transcriptional changes of genes and proteins involved in MSR characteristics, principally within the astrocyte unit rather than microglia and oligodendrocytes. In brief, our work provides evidence that MSR has an active role in the pathogenesis of AD, as reducing mitochondrial homeostasis via atf4 depletion in AD mice aggravates the hallmarks of the disease; conversely, bolstering mitochondrial proteostasis(definition) by NMN decreases protein aggregation, restores memory performance, and delays disease progression, ultimately translating to increased healthspan(definition).
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1038/s41419-024-07062-1
- Canonical
- link ↗
- Fetched
- 2026-11-12 MST
Cite this
APA
Xiong, X., Hou, J., Zheng, Y., Jiang, T., Zhao, X., Cai, J., Huang, J., He, H., Xu, J., Qian, S., Lü, Y., Wang, X., Wang, W., Ye, Q., Zhou, S., Lian, M., Xiao, J., Song, W., & Xie, C. (2024). NAD+-boosting agent nicotinamide mononucleotide potently improves mitochondria stress response in Alzheimer’s disease via ATF4-dependent mitochondrial UPR. <em>Cell Death and Disease</em>. https://doi.org/10.1038/s41419-024-07062-1
Vancouver
Xiong X, Hou J, Zheng Y, Jiang T, Zhao X, Cai J, et al. NAD+-boosting agent nicotinamide mononucleotide potently improves mitochondria stress response in Alzheimer’s disease via ATF4-dependent mitochondrial UPR. Cell Death and Disease. 2024. doi:10.1038/s41419-024-07062-1.
BibTeX
@article{xi2024NADboo,
title = {NAD+-boosting agent nicotinamide mononucleotide potently improves mitochondria stress response in Alzheimer’s disease via ATF4-dependent mitochondrial UPR},
author = {Xi Xiong and Jialong Hou and Yi Zheng and Tao Jiang and Xuemiao Zhao and Jinlai Cai and Jiani Huang and Haijun He and Jiaxue Xu and Shuangjie Qian and Yao Lü and Xinshi Wang and Wenwen Wang and Qianqian Ye and Shuoting Zhou and Mengjia Lian and Jian Xiao and Weihong Song and Chenglong Xie},
journal = {Cell Death and Disease},
year = {2024},
doi = {10.1038/s41419-024-07062-1},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Proceedings of the National Academy of Sciences 2009
Preprint · OA
Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease
Experimental Neurology 2020
Citation only
Purified oleocanthal and ligstroside protect against mitochondrial dysfunction in models of early Alzheimer's disease and brain ageing
Cell Reports 2018
Open access · CC-BY
The NAD+ Precursor Nicotinamide Riboside Rescues Mitochondrial Defects and Neuronal Loss in iPSC and Fly Models of Parkinson’s Disease
JCI Insight 2017
Open access · OA
Nicotinamide mononucleotide requires SIRT3 to improve cardiac function and bioenergetics in a Friedreich’s ataxia cardiomyopathy model
Current Neurology and Neuroscience Reports 2018
Open access · CC-BY
Mitochondrial Dysfunction in Parkinson’s Disease: New Mechanistic Insights and Therapeutic Perspectives
Veterinary sciences 2026
Open access · OA